Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 5/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.50 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12093537 | 0.87 | MMP13 (0.61) | NAMPTHDAC4HDAC3HDAC8ROCK2 | |
| SCHEMBL12156536 | 0.86 | CA2 (0.57) | NAMPTHDAC4HDAC3HDAC8HDAC1 | |
| SCHEMBL12090016 | 0.86 | NAMPT (0.58) | NAMPTHDAC4HDAC3HDAC8ROCK2 | |
| SCHEMBL22122859 | 0.85 | NAMPT (0.66) | NAMPTHDAC4HDAC3HDAC8ROCK2 | |
| Hydrochloric Acid SCHEMBL5115404 | 0.85 | CA2 (0.56) | NAMPTHDAC4HDAC3HDAC8HDAC1 | |
| SCHEMBL19226529 | 0.84 | NAMPT (0.59) | NAMPTHDAC4HDAC3HDAC8ROCK2 | |
| SCHEMBL3123586 | 0.84 | KDM4E (0.54) | NAMPTHDAC4HDAC3HDAC8HDAC1 | |
| SCHEMBL24331631 | 0.83 | CA2 (0.67) | NAMPTHDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL19145458 | 0.83 | NAMPT (0.43) | NAMPTHDAC4HDAC3HDAC8HTR4 | |
| SCHEMBL1448089 | 0.83 | NAMPT (0.57) | NAMPTHDAC4HDAC3HDAC8ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3802492-B1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2024-11-06 | — | — | EP | disclosed |
| US-11970469-B2 | Compounds useful in the treatment of disorders associated with mutant RAS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-04-30 | — | — | US | disclosed |
| US-20210214322-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214322-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | KRAS, NRAS, HRAS | NAMPT 3451/4885HDAC4 2867/4885HDAC3 3575/4885 |
| US-11970469-B2 | Compounds useful in the treatment of disorders associated with mutant RAS | KRAS, NRAS, HRAS | NAMPT 3451/4885HDAC4 2867/4885HDAC3 3575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.